Open AccessFat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine
Author(s) -
Lambert Assoumou,
Chrystèle Racine,
Soraya Fellahi,
Antonin Lamazière,
Dominique Farabos,
Lydie Béniguel,
JeanPhilippe Bastard,
Bruno Fève,
Séverine Gibowski,
Christine Katlama,
Dominique Costagliola,
Jacqueline Capeau
Publication year - 2020
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002644
Subject(s) - raltegravir , etravirine , weight gain , insulin resistance , medicine , hormone , endocrinology , physiology , human immunodeficiency virus (hiv) , viral load , insulin , virology , body weight , antiretroviral therapy
: Fat gain is reported in integrase strand transfer inhibitors exposed persons living with HIV. We investigated in 165 persons living with HIV (117 men/48 women), included in the 96-week ANRS-163-ETRAL trial and switched to raltegravir/etravirine, the impact of sex, menopausal status and ovarian reserve (detectable anti-Müllerian hormone). From baseline to 48/96 weeks, women with ovarian reserve were protected from raltegravir/etravirine-induced weight/fat gain and associated insulin-resistance while peri/postmenopausal women increased weight, fat and insulin resistance as did men. The functional ovarian status could protect against raltegravir/etravirine-induced weight gain.